ONCOBIOME
DEAD

Serial Number

86300247

Owner

VL28, Inc.

Attorney

Heather E Balmat

Filing Date

Jun 4, 2014

Add to watchlist:

No watchlists yet
View on USPTO

ONCOBIOME Trademark

Serial Number: 86300247

ONCOBIOME is a trademark filed by VL28, Inc. on June 4, 2014. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

VL28, Inc. (4 trademarks)

7th Floor
Cambridge, VA 02142

Entity Type: 03

EVELO THERAPEUTICS, INC. (4 trademarks)

Suite 200W
CAMBRIDGE, MA 02139

Entity Type: 03

Trademark Details

Filing Date

June 4, 2014

Registration Date

Not Registered

Goods & Services

scientific, analytical, and statistical computer software for creating and managing databases containing genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data derived from patient clinical care information and medical research data; computer software for analyzing and creating statistical models derived from patient clinical care information and medical research data in the nature of genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data

microbial preparations for pharmaceutical, veterinary and medical purposes, namely, microbial preparations for use as tumor suppressing agents, immuno-suppressing agents, immuno-stimulating agents, and anti-cancer agents; dietary supplements, nutritional supplements, nutraceuticals for use as dietary supplements, food supplements, nutritionally fortified vegetable-based food, beverages, and nutritional food bars, all of the foregoing containing microorganisms for medical, therapeutic, or preventative purposes; therapeutic pharmaceuticals containing microorganisms for medical and veterinary use for the treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers, and metastases; therapeutic pharmaceuticals containing derivatives of microorganisms for medical and veterinary use for the treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers, and metastases; pharmaceutical, veterinary and medical preparations and substances, namely, anti-microbial preparations and substances, anti-bacterial, anti-fungal, anti-viral, and anti-protist preparations and substances, all for the treatment of cancer, cancer symptoms, cancer-related diseases, and side-effects of cancer therapies; anti-cancer preparations and substances; preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals, namely, combination preparations containing in majority part antimicrobial preparations and lesser amounts of microbial preparations and anti-cancer preparations for use as a preservative; pharmaceutical preparations and substances for the treatment of cancer, namely, microbial and anti-microbial preparations for veterinary and medical use; anti-cancer preparations for use in treating cancer symptoms, cancer-related diseases, and side-effects of cancer therapies; pharmaceutical preparations for the treatment of infectious diseases and cancer, namely, combination preparations of anti-cancer agents, microbial preparations and anti-microbial preparations; diagnostic kits for diagnosing disease, determination of likelihood of disease, prognosis of responsiveness to therapy and/or patient prognosis comprised of diagnostic reagents and buffers for the detection of microbes, viral, bacterial, fungal, and parasitic or non-parasitic protist infections, inflammation, and biomarkers associated with pre-neoplastic lesions, neoplasms, tumors, cancers, or metastases; preparations for detecting mutations in genes for medical purposes as used in the collection of large-scale genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic medical data and related clinical data

medical clinics; veterinary dentistry; behavioural analysis for medical purposes; genetic testing for medical purposes; collection and preservation of human blood for medical purposes; medical diagnostic testing for assessing pre-neoplastic lesions, neoplasms, tumors, cancers, or metastases

medical diagnostic instruments for screening, assessing, and determining appropriate courses of treatment in relation to pre-neoplastic lesions, neoplasms, tumors, cancers and metastases

electronic data storage services, namely, electronic storage of large-scale genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data and related clinical data for treatment and diagnostic purposes; database, computer-readable program and software development services, namely, development of scientific, analytical, and statistical software and related databases for use in conjunction with genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data gathered from patient clinical care information and medical research data; scientific, chemical, biochemical and microbiological research; scientific research in the field of genetics and genetic engineering of microbes; scientific research in the field of genetic and molecular tests, including tests for microbial populations in vertebrate samples; research and development of therapeutic pharmaceuticals, consumer medical products, diagnostic equipment and prognostic tools consisting of genetically engineered microorganisms, combinations of microorganisms, and individually selected microorganisms for treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers and metastases

Filing History

ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT
Oct 2, 2017 MAB1
ABANDONMENT - EXPRESS MAILED
Oct 2, 2017 ABN1
EXPARTE APPEAL TERMINATED
Sep 21, 2017 EXPT
EXPARTE APPEAL DISMISSED AS MOOT
Sep 21, 2017 EXDM
NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Jul 21, 2017 GEA1
ACTION DENYING REQ FOR RECON E-MAILED
Jul 21, 2017 GECD
ACTION CONTINUING FINAL - COMPLETED
Jul 21, 2017 CNCF
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 3, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 3, 2017 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 29, 2017 ERFR
EX PARTE APPEAL-INSTITUTED
Jun 29, 2017 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jun 29, 2017 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Jun 29, 2017 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 29, 2016 GNFN
FINAL REFUSAL E-MAILED
Dec 29, 2016 GNFR
FINAL REFUSAL WRITTEN
Dec 29, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 6, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 5, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 5, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 3, 2016 GNRN
NON-FINAL ACTION E-MAILED
Jun 3, 2016 GNRT
NON-FINAL ACTION WRITTEN
Jun 3, 2016 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 13, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 13, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 13, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 13, 2015 GNRN
NON-FINAL ACTION E-MAILED
Nov 13, 2015 GNRT
NON-FINAL ACTION WRITTEN
Nov 13, 2015 CNRT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 4, 2015 ASGN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 26, 2015 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 26, 2015 COAR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 23, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 22, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 22, 2015 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 22, 2015 GNRN
NON-FINAL ACTION E-MAILED
Apr 22, 2015 GNRT
NON-FINAL ACTION WRITTEN
Apr 22, 2015 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 1, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 1, 2015 CRFA
ASSIGNED TO LIE
Mar 30, 2015 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 21, 2015 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 2, 2015 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 2, 2015 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 23, 2014 GNRN
NON-FINAL ACTION E-MAILED
Sep 23, 2014 GNRT
NON-FINAL ACTION WRITTEN
Sep 23, 2014 CNRT
ASSIGNED TO EXAMINER
Sep 16, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 19, 2014 NWOS